SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Cumali Efe; Koray Taşçılar; Alessio Gerussi; Francesca Bolis; Craig Lammert; Berat Ebik; Albert Friedrich Stättermayer; Mustafa Cengiz; Dilara Turan Gökçe; Laura Cristoferi; Mirta Peralta; Hatef Massoumi; Pedro Montes; Eira Cerda; Cristina Rigamonti; Suna Yapalı; Gupse Adali; Ali Rıza Çalışkan; Yasemin Balaban; Fatih Eren; Tuğçe Eşkazan; Sezgin Barutçu; Ellina Lytvyak; Godolfino Miranda Zazueta; Meral Akdogan Kayhan; Alexandra Heurgue-Berlot; Eleonora De Martin; Ahmet Yavuz; Murat Bıyık; Graciela Castro Narro; Serkan Duman; Nelia Hernandez; Nikolaos K. Gatselis; Jonathan Aguirre; Ramazan Idilman; Marcelo Silva; Manuel Mendizabal; Kadri Atay; Fatih Güzelbulut; Renumathy Dhanasekaran; Aldo J. Montano-Loza; George N. Dalekos; Ezequiel Ridruejo; Pietro Invernizzi; Staffan Wahlin

doi:10.1016/j.jaut.2022.102906

SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Cumali Efe, Koray Taşçılar, Alessio Gerussi, Francesca Bolis, Craig Lammert, Berat Ebik, Albert Friedrich Stättermayer, Mustafa Cengiz, Dilara Turan Gökçe, Laura Cristoferi, Mirta Peralta, Hatef Massoumi, Pedro Montes, Eira Cerda, Cristina Rigamonti, Suna Yapalı, Gupse Adali, Ali Rıza Çalışkan, Yasemin Balaban, Fatih ErenTuğçe Eşkazan, Sezgin Barutçu, Ellina Lytvyak, Godolfino Miranda Zazueta, Meral Akdogan Kayhan, Alexandra Heurgue-Berlot, Eleonora De Martin, Ahmet Yavuz, Murat Bıyık, Graciela Castro Narro, Serkan Duman, Nelia Hernandez, Nikolaos K. Gatselis, Jonathan Aguirre, Ramazan Idilman, Marcelo Silva, Manuel Mendizabal, Kadri Atay, Fatih Güzelbulut, Renumathy Dhanasekaran, Aldo J. Montano-Loza, George N. Dalekos, Ezequiel Ridruejo, Pietro Invernizzi, Staffan Wahlin

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.

Lingua originale	Inglese
Numero di articolo	102906
Rivista	Journal of Autoimmunity
Volume	132
DOI	https://doi.org/10.1016/j.jaut.2022.102906
Stato di pubblicazione	Pubblicato - ott 2022

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.jaut.2022.102906

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Efe, C., Taşçılar, K., Gerussi, A., Bolis, F., Lammert, C., Ebik, B., Stättermayer, A. F., Cengiz, M., Gökçe, D. T., Cristoferi, L., Peralta, M., Massoumi, H., Montes, P., Cerda, E., Rigamonti, C., Yapalı, S., Adali, G., Çalışkan, A. R., Balaban, Y., ... Wahlin, S. (2022). SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of Autoimmunity, 132, Articolo 102906. https://doi.org/10.1016/j.jaut.2022.102906

@article{74865594e28949e3b3f151103f29ed57,

title = "SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis",

abstract = "Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81\%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4\% vs. 14.2\%), need for any supplemental oxygen (29.5\% vs. 9\%) and mortality (7\% vs. 0.6\%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95\% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95\% CI 0.11–0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.",

keywords = "Autoimmunity, Breakthrough infection, Immunosuppression, Liver failure, Vaccine",

author = "Cumali Efe and Koray Ta{\c s}{\c c}ılar and Alessio Gerussi and Francesca Bolis and Craig Lammert and Berat Ebik and St{\"a}ttermayer, \{Albert Friedrich\} and Mustafa Cengiz and G{\"o}k{\c c}e, \{Dilara Turan\} and Laura Cristoferi and Mirta Peralta and Hatef Massoumi and Pedro Montes and Eira Cerda and Cristina Rigamonti and Suna Yapalı and Gupse Adali and {\c C}alı{\c s}kan, \{Ali Rıza\} and Yasemin Balaban and Fatih Eren and Tuğ{\c c}e E{\c s}kazan and Sezgin Barut{\c c}u and Ellina Lytvyak and Zazueta, \{Godolfino Miranda\} and Kayhan, \{Meral Akdogan\} and Alexandra Heurgue-Berlot and \{De Martin\}, Eleonora and Ahmet Yavuz and Murat Bıyık and Narro, \{Graciela Castro\} and Serkan Duman and Nelia Hernandez and Gatselis, \{Nikolaos K.\} and Jonathan Aguirre and Ramazan Idilman and Marcelo Silva and Manuel Mendizabal and Kadri Atay and Fatih G{\"u}zelbulut and Renumathy Dhanasekaran and Montano-Loza, \{Aldo J.\} and Dalekos, \{George N.\} and Ezequiel Ridruejo and Pietro Invernizzi and Staffan Wahlin",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = oct,

doi = "10.1016/j.jaut.2022.102906",

language = "English",

volume = "132",

journal = "Journal of Autoimmunity",

issn = "0896-8411",

publisher = "Academic Press",

}

Efe, C, Taşçılar, K, Gerussi, A, Bolis, F, Lammert, C, Ebik, B, Stättermayer, AF, Cengiz, M, Gökçe, DT, Cristoferi, L, Peralta, M, Massoumi, H, Montes, P, Cerda, E, Rigamonti, C, Yapalı, S, Adali, G, Çalışkan, AR, Balaban, Y, Eren, F, Eşkazan, T, Barutçu, S, Lytvyak, E, Zazueta, GM, Kayhan, MA, Heurgue-Berlot, A, De Martin, E, Yavuz, A, Bıyık, M, Narro, GC, Duman, S, Hernandez, N, Gatselis, NK, Aguirre, J, Idilman, R, Silva, M, Mendizabal, M, Atay, K, Güzelbulut, F, Dhanasekaran, R, Montano-Loza, AJ, Dalekos, GN, Ridruejo, E, Invernizzi, P & Wahlin, S 2022, 'SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis', Journal of Autoimmunity, vol. 132, 102906. https://doi.org/10.1016/j.jaut.2022.102906

TY - JOUR

T1 - SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

AU - Efe, Cumali

AU - Taşçılar, Koray

AU - Gerussi, Alessio

AU - Bolis, Francesca

AU - Lammert, Craig

AU - Ebik, Berat

AU - Stättermayer, Albert Friedrich

AU - Cengiz, Mustafa

AU - Gökçe, Dilara Turan

AU - Cristoferi, Laura

AU - Peralta, Mirta

AU - Massoumi, Hatef

AU - Montes, Pedro

AU - Cerda, Eira

AU - Rigamonti, Cristina

AU - Yapalı, Suna

AU - Adali, Gupse

AU - Çalışkan, Ali Rıza

AU - Balaban, Yasemin

AU - Eren, Fatih

AU - Eşkazan, Tuğçe

AU - Barutçu, Sezgin

AU - Lytvyak, Ellina

AU - Zazueta, Godolfino Miranda

AU - Kayhan, Meral Akdogan

AU - Heurgue-Berlot, Alexandra

AU - De Martin, Eleonora

AU - Yavuz, Ahmet

AU - Bıyık, Murat

AU - Narro, Graciela Castro

AU - Duman, Serkan

AU - Hernandez, Nelia

AU - Gatselis, Nikolaos K.

AU - Aguirre, Jonathan

AU - Idilman, Ramazan

AU - Silva, Marcelo

AU - Mendizabal, Manuel

AU - Atay, Kadri

AU - Güzelbulut, Fatih

AU - Dhanasekaran, Renumathy

AU - Montano-Loza, Aldo J.

AU - Dalekos, George N.

AU - Ridruejo, Ezequiel

AU - Invernizzi, Pietro

AU - Wahlin, Staffan

PY - 2022/10

Y1 - 2022/10

N2 - Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.

AB - Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.

KW - Autoimmunity

KW - Breakthrough infection

KW - Immunosuppression

KW - Liver failure

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85137350048

U2 - 10.1016/j.jaut.2022.102906

DO - 10.1016/j.jaut.2022.102906

M3 - Article

SN - 0896-8411

VL - 132

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

M1 - 102906

ER -

SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo